TY - JOUR
T1 - Organoid
T2 - Biomedical application, biobanking, and pathways to translation
AU - Sinha, Aprajita
AU - Maibam, Maheshree
AU - Jain, Ronit
AU - Aggarwal, Kalash
AU - Sahu, Asish Kumar
AU - Gupta, Pawan
AU - Paul, Sayan
AU - Bisht, Bharti
AU - Paul, Manash K.
N1 - Publisher Copyright:
© 2025
PY - 2025/5
Y1 - 2025/5
N2 - Organoids are tiny stem cell-derived 3D in vitro cell culture systems mimicking the structural and functional aspects of the tissues in the human body and provide a means to study complex bio-physiological processes in normal and disease states (disease modeling) and also for therapeutic screening and clinical trials. Scientists have now developed protocols to maintain and use organoids from diverse human tissues, including the gut, liver, brain, and pancreas, and they have the potential to reduce or remove the dependency on animal models and have research utility and translational potential. One major advantage is that they can be generated from patients with specific genetic diseases, thereby providing options for exploring personalized medicine and rare diseases lacking robust animal models. Recent advances in multi-omics technologies, imaging technologies, biomaterial chemistry, bioengineering, microfluidics, and stem cell research have revolutionized organoid bioengineering, opening the opportunity for mass production, biobanking, and commercialization.
AB - Organoids are tiny stem cell-derived 3D in vitro cell culture systems mimicking the structural and functional aspects of the tissues in the human body and provide a means to study complex bio-physiological processes in normal and disease states (disease modeling) and also for therapeutic screening and clinical trials. Scientists have now developed protocols to maintain and use organoids from diverse human tissues, including the gut, liver, brain, and pancreas, and they have the potential to reduce or remove the dependency on animal models and have research utility and translational potential. One major advantage is that they can be generated from patients with specific genetic diseases, thereby providing options for exploring personalized medicine and rare diseases lacking robust animal models. Recent advances in multi-omics technologies, imaging technologies, biomaterial chemistry, bioengineering, microfluidics, and stem cell research have revolutionized organoid bioengineering, opening the opportunity for mass production, biobanking, and commercialization.
UR - https://www.scopus.com/pages/publications/105004467967
UR - https://www.scopus.com/inward/citedby.url?scp=105004467967&partnerID=8YFLogxK
U2 - 10.1016/j.heliyon.2025.e43028
DO - 10.1016/j.heliyon.2025.e43028
M3 - Review article
AN - SCOPUS:105004467967
SN - 2405-8440
VL - 11
JO - Heliyon
JF - Heliyon
IS - 10
M1 - e43028
ER -